An interventional study of alivis in Borderline Personality Disorder (BPD), sponsored by Gaia AG. Terminated at 1 site in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-16.
Sponsored by Gaia AG · Not applicable, Interventional, and Treatment
This randomized controlled trial (RCT) with 470 patients diagnosed with Borderline Personality Disorder (BPD) aims to investigate the effectiveness of the unguided digital therapeutic alivis for patients with BPD as defined in DSM-5. Inclusion criteria are: male, female or non-binary, age 18-65 years, diagnosis of BPD (confirmed by SCID-5-PD), borderline severity score (cut-off) of ≥ 1.07 on the Borderline Symptoms List 23 (BSL-23), stable treatment (psychotherapy, medication, no treatment, …) for at least 30 days at the time of inclusion, consent to emergency plan for suicidal crises, consent to participation, and sufficient German language skills. Exclusion criteria are: Plans to change in treatment (psychotherapy, medication, …) in the upcoming 6 months after inclusion, comorbid diagnosis of substance use disorder or lifetime diagnosis of psychotic disorder, physical condition that can cause severe psychiatric symptoms, acute decompensation of mental health, BMI \<15, and prior use of the digital intervention priovi.
Patients will be randomized and allocated to either an intervention group, in which they will receive access to alivis in addition to treatment as usual (TAU; n=235), or to a control group, in which they will receive access to TAU (n=235).
The primary endpoint will be BPD symptoms with three months post-allocation (T1) being the primary timepoint for assessment of effectiveness. Six (T2) and twelve (T3) months post-allocation will be used as follow-up assessment of endpoints. Secondary endpoints will be depressive symptoms, anxiety symptoms, costs caused due to the patient's BPD, social functioning, health-related quality of life, and patient activation.
Exclusion Criteria:
Participants in the intervention group will receive access to alivis in addition to treatment as usual (TAU) for 12 months.
Behavioral: alivis
Participants in the control group will receive access to treatment as usual (TAU) only. They will receive access to alivis after their last study visit (T3; 12 months after randomization).
alivis is an interactive online program for independent use by users with Borderline Personality Disorder. It focuses on recognized treatment elements from Dialectical Behavior Therapy, Schema Therapy, Acceptance and Commitment Therapy, and Mindfulness Self-Compassion Therapy.
Borderline Symptoms List 23 (BSL-23)
The BSL-23 is a 23-item PROM with good psychometric properties that was validated and tested for reliability in a representative German sample (test-retest reliability r = .82, p \< 0.0001; α = 0.94-0.97; high correlation of total score with general psychological burden and depression) to assess the typical symptomatology and severity of BPD. It refers to the last week and has a range from 0 = "not at all" to 4 = "very strong". Its single factor structure was optimized to reflect levels and changes in severity of BPD-symptomatology based on a mean score. Higher mean scores indicate greater symptom severity and thus a worse outcome, whereas lower scores indicate fewer BPD-related symptoms and a better outcome.
Time frame: T1 (3 months after randomization)
Patient Health Questionnaire 9 (PHQ-9)
The PHQ-9 is the 9-item depression module from the full PHQ with comparable sensitivity and specificity, and includes the 9 criteria upon which the diagnosis of DSM-IV depressive disorders is based. Rating is done on a 4-point Likert scale ranging 0 = "not at all" to 3 = "nearly every day". As a severity measure, scores range from 0 to 27 and represent: mild (0-4), moderate (5-9), moderately severe (10-14), and severe depression (≥15). According to several studies, the German version can be considered reliable regarding psychometric standards. Higher total scores indicate greater depressive symptom severity and thus a worse outcome, whereas lower scores indicate fewer depressive symptoms and a better outcome.
Time frame: T1 (3 months after randomization)
Generalized Anxiety Disorder Assessment 7 (GAD-7)
This self-administered patient questionnaire is used as a screening tool and severity measure for generalized anxiety disorder (GAD). Studies report good reliability, as well as criterion, construct, factorial, and procedural validity. The GAD-7 is scored on a Likert scale ranging from 0 = "not at all" via 1 = "several days" and 2 = "more than half the days" to 3 = "nearly every day", yielding a sum score ranging from 0-21. Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively. Higher total scores indicate greater anxiety symptom severity and thus a worse outcome, whereas lower scores indicate fewer anxiety symptoms and a better outcome.
Time frame: T1 (3 months after randomization)
Costs Caused Due to the Patients BPD
Costs caused due to BPD will be assessed with a self-compiled instrument assessing inpatient and outpatient treatment, support from friends, family and professional services, contacts with members of the judicial authorities and public security, medication, sick leave, and physician/therapist visits during work time. Higher values indicate greater resource utilization and higher costs and thus a worse economic outcome, whereas lower values indicate lower resource use and a better economic outcome.
Time frame: T1 (3 months after randomization)
Work and Social Adjustment Scale (WSAS)
The WSAS is a 5-item self-report scale to measure social functioning in regard to physical, mental and social health as well as age group referenced competence for performance. The PROM has good psychometric properties with good criterion validity, good sensitivity and strong internal consistency (α = 0.89). Individual items address work, home management, social leisure, private leisure and relationships. Each item is rated on a 9-point Likert scale from 0 = "not at all impaired" to 8 = "very severely impaired". The total score ranges from 0 to 40. Higher total scores indicate greater functional impairment and thus a worse outcome, whereas lower scores indicate less disability and a better outcome.
Time frame: T1 (3 months after randomization)
Patient Activation Measure (PAM-13)
The PAM-13 assesses patients' active participation in their medical care using 13 items. Items are answered on a Likert scale ranging from 1 = "strongly disagree" to 4 = "strongly agree," yielding a raw total score between 13 and 52. The German version of the PAM-13 (PAM-13-G) is validated and demonstrates good psychometric properties, including good internal consistency (Cronbach's α = 0.84). In this study, raw scores were converted into the standardized 0-100 patient activation score using a min-max transformation, with higher scores indicating greater patient activation and thus a better outcome.
Time frame: T1 (3 months after randomization)
Assessment of Quality of Life 8 Dimensions (AQoL-8D)
The AQoL-8D is a health-related quality-of-life questionnaire consisting of 35 items forming eight health dimensions: independent living, happiness, mental health, coping, relationships, self worth, pain, senses. Validation of the AQoL-8D assessing health-related quality of life showed good psychometric properties in a German patient sample, including excellent reliability (Cronbach's α = 0.96) and construct validity (strong correlation with the SF-36, r = .81). The AQoL-8D score ranges from 0-100; higher scores indicating higher quality of life.
Time frame: T1 (3 months after randomization)
Assessment of Quality of Life 8 Dimensions (AQoL-8D)
The AQoL-8D is a health-related quality-of-life questionnaire consisting of 35 items forming eight health dimensions: independent living, happiness, mental health, coping, relationships, self worth, pain, senses. Validation of the AQoL-8D assessing health-related quality of life showed good psychometric properties in a German patient sample, including excellent reliability (Cronbach's α = 0.96) and construct validity (strong correlation with the SF-36, r = .81). The AQoL-8D score ranges from 0-100; higher scores indicating higher quality of life.
Time frame: T2 (6 months after randomization); T3 (12 months after randomization)
Patient Activation Measure (PAM-13)
The PAM-13 assesses patients' active participation in their medical care using 13 items. Items are answered on a Likert scale ranging from 1 = "strongly disagree" to 4 = "strongly agree," yielding a raw total score between 13 and 52. The German version of the PAM-13 (PAM-13-G) is validated and demonstrates good psychometric properties, including good internal consistency (Cronbach's α = 0.84). In this study, raw scores were converted into the standardized 0-100 patient activation score using a min-max transformation, with higher scores indicating greater patient activation and thus a better outcome.
Time frame: T2 (6 months after randomization); T3 (12 months after randomization)
Work and Social Adjustment Scale (WSAS)
The WSAS is a 5-item self-report scale to measure social functioning in regard to physical, mental and social health as well as age group referenced competence for performance. The PROM has good psychometric properties with good criterion validity, good sensitivity and strong internal consistency (α = 0.89). Individual items address work, home management, social leisure, private leisure and relationships. Each item is rated on a 9-point Likert scale from 0 = "not at all impaired" to 8 = "very severely impaired". The total score ranges from 0 to 40. Higher total scores indicate greater functional impairment and thus a worse outcome, whereas lower scores indicate less disability and a better outcome.
Time frame: T2 (6 months after randomization); T3 (12 months after randomization)
Costs Caused Due to the Patients BPD
Costs caused due to BPD will be assessed with a self-compiled instrument assessing inpatient and outpatient treatment, support from friends, family and professional services, contacts with members of the judicial authorities and public security, medication, sick leave, and physician/therapist visits during work time. Higher values indicate greater resource utilization and higher costs and thus a worse economic outcome, whereas lower values indicate lower resource use and a better economic outcome.
Time frame: T2 (6 months after randomization); T3 (12 months after randomization)
Generalized Anxiety Disorder Assessment 7 (GAD-7)
This self-administered patient questionnaire is used as a screening tool and severity measure for generalized anxiety disorder (GAD). Studies report good reliability, as well as criterion, construct, factorial, and procedural validity. The GAD-7 is scored on a Likert scale ranging from 0 = "not at all" via 1 = "several days" and 2 = "more than half the days" to 3 = "nearly every day", yielding a sum score ranging from 0-21. Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively. Higher total scores indicate greater anxiety symptom severity and thus a worse outcome, whereas lower scores indicate fewer anxiety symptoms and a better outcome.
Time frame: T2 (6 months after randomization); T3 (12 months after randomization)
Patient Health Questionnaire 9 (PHQ-9)
The PHQ-9 is the 9-item depression module from the full PHQ with comparable sensitivity and specificity, and includes the 9 criteria upon which the diagnosis of DSM-IV depressive disorders is based. Rating is done on a 4-point Likert scale ranging 0 = "not at all" to 3 = "nearly every day". As a severity measure, scores range from 0 to 27 and represent: mild (0-4), moderate (5-9), moderately severe (10-14), and severe depression (≥15). According to several studies, the German version can be considered reliable regarding psychometric standards. Higher total scores indicate greater depressive symptom severity and thus a worse outcome, whereas lower scores indicate fewer depressive symptoms and a better outcome.
Time frame: T2 (6 months after randomization); T3 (12 months after randomization)
Borderline Symptoms List 23 (BSL-23)
The BSL-23 is a 23-item PROM with good psychometric properties that was validated and tested for reliability in a representative German sample (test-retest reliability r = .82, p \< 0.0001; α = 0.94-0.97; high correlation of total score with general psychological burden and depression) to assess the typical symptomatology and severity of BPD. It refers to the last week and has a range from 0 = "not at all" to 4 = "very strong". Its single factor structure was optimized to reflect levels and changes in severity of BPD-symptomatology based on a mean score. Higher mean scores indicate greater symptom severity and thus a worse outcome, whereas lower scores indicate fewer BPD-related symptoms and a better outcome.
Time frame: T2 (6 months after randomization); T3 (12 months after randomization)
| Milestone | Alivis + Treatment as Usual (TAU) | Treatment as Usual (TAU) |
|---|---|---|
| Started | 142 | 144 |
| Completed | 97 | 96 |
| Not completed | 45 | 48 |
The BSL-23 is a 23-item PROM with good psychometric properties that was validated and tested for reliability in a representative German sample (test-retest reliability r = .82, p \< 0.0001; α = 0.94-0.97; high correlation of total score with general psychological burden and depression) to assess the typical symptomatology and severity of BPD. It refers to the last week and has a range from 0 = "not at all" to 4 = "very strong". Its single factor structure was optimized to reflect levels and changes in severity of BPD-symptomatology based on a mean score. Higher mean scores indicate greater symptom severity and thus a worse outcome, whereas lower scores indicate fewer BPD-related symptoms and a better outcome.
| Score | Alivis + Treatment as Usual (TAU) | Treatment as Usual (TAU) |
|---|---|---|
| Borderline Symptoms List 23 (BSL-23) | 1.95 ± 0.78 | 2.00 ± 0.80 |
The PHQ-9 is the 9-item depression module from the full PHQ with comparable sensitivity and specificity, and includes the 9 criteria upon which the diagnosis of DSM-IV depressive disorders is based. Rating is done on a 4-point Likert scale ranging 0 = "not at all" to 3 = "nearly every day". As a severity measure, scores range from 0 to 27 and represent: mild (0-4), moderate (5-9), moderately severe (10-14), and severe depression (≥15). According to several studies, the German version can be considered reliable regarding psychometric standards. Higher total scores indicate greater depressive symptom severity and thus a worse outcome, whereas lower scores indicate fewer depressive symptoms and a better outcome.
| Score | Alivis + Treatment as Usual (TAU) | Treatment as Usual (TAU) |
|---|---|---|
| Patient Health Questionnaire 9 (PHQ-9) | 15.3 ± 4.7 | 15.8 ± 5.2 |
This self-administered patient questionnaire is used as a screening tool and severity measure for generalized anxiety disorder (GAD). Studies report good reliability, as well as criterion, construct, factorial, and procedural validity. The GAD-7 is scored on a Likert scale ranging from 0 = "not at all" via 1 = "several days" and 2 = "more than half the days" to 3 = "nearly every day", yielding a sum score ranging from 0-21. Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively. Higher total scores indicate greater anxiety symptom severity and thus a worse outcome, whereas lower scores indicate fewer anxiety symptoms and a better outcome.
| Score | Alivis + Treatment as Usual (TAU) | Treatment as Usual (TAU) |
|---|---|---|
| Generalized Anxiety Disorder Assessment 7 (GAD-7) | 12.3 ± 4.2 | 12.2 ± 4.1 |
Costs caused due to BPD will be assessed with a self-compiled instrument assessing inpatient and outpatient treatment, support from friends, family and professional services, contacts with members of the judicial authorities and public security, medication, sick leave, and physician/therapist visits during work time. Higher values indicate greater resource utilization and higher costs and thus a worse economic outcome, whereas lower values indicate lower resource use and a better economic outcome.
| € | Alivis + Treatment as Usual (TAU) | Treatment as Usual (TAU) |
|---|---|---|
| Costs Caused Due to the Patients BPD | 2354.8 ± 5619.7 | 3290.9 ± 7468.0 |
The WSAS is a 5-item self-report scale to measure social functioning in regard to physical, mental and social health as well as age group referenced competence for performance. The PROM has good psychometric properties with good criterion validity, good sensitivity and strong internal consistency (α = 0.89). Individual items address work, home management, social leisure, private leisure and relationships. Each item is rated on a 9-point Likert scale from 0 = "not at all impaired" to 8 = "very severely impaired". The total score ranges from 0 to 40. Higher total scores indicate greater functional impairment and thus a worse outcome, whereas lower scores indicate less disability and a better outcome.
| Score | Alivis + Treatment as Usual (TAU) | Treatment as Usual (TAU) |
|---|---|---|
| Work and Social Adjustment Scale (WSAS) | 22.0 ± 8.0 | 22.1 ± 7.9 |
The PAM-13 assesses patients' active participation in their medical care using 13 items. Items are answered on a Likert scale ranging from 1 = "strongly disagree" to 4 = "strongly agree," yielding a raw total score between 13 and 52. The German version of the PAM-13 (PAM-13-G) is validated and demonstrates good psychometric properties, including good internal consistency (Cronbach's α = 0.84). In this study, raw scores were converted into the standardized 0-100 patient activation score using a min-max transformation, with higher scores indicating greater patient activation and thus a better outcome.
| Score | Alivis + Treatment as Usual (TAU) | Treatment as Usual (TAU) |
|---|---|---|
| Patient Activation Measure (PAM-13) | 65.9 ± 13.0 | 65.7 ± 11.9 |
The AQoL-8D is a health-related quality-of-life questionnaire consisting of 35 items forming eight health dimensions: independent living, happiness, mental health, coping, relationships, self worth, pain, senses. Validation of the AQoL-8D assessing health-related quality of life showed good psychometric properties in a German patient sample, including excellent reliability (Cronbach's α = 0.96) and construct validity (strong correlation with the SF-36, r = .81). The AQoL-8D score ranges from 0-100; higher scores indicating higher quality of life.
| Score | Alivis + Treatment as Usual (TAU) | Treatment as Usual (TAU) |
|---|---|---|
| Assessment of Quality of Life 8 Dimensions (AQoL-8D) | 49.9 ± 10.6 | 50.0 ± 11.1 |
The AQoL-8D is a health-related quality-of-life questionnaire consisting of 35 items forming eight health dimensions: independent living, happiness, mental health, coping, relationships, self worth, pain, senses. Validation of the AQoL-8D assessing health-related quality of life showed good psychometric properties in a German patient sample, including excellent reliability (Cronbach's α = 0.96) and construct validity (strong correlation with the SF-36, r = .81). The AQoL-8D score ranges from 0-100; higher scores indicating higher quality of life.
Results for this outcome have not been posted.
The PAM-13 assesses patients' active participation in their medical care using 13 items. Items are answered on a Likert scale ranging from 1 = "strongly disagree" to 4 = "strongly agree," yielding a raw total score between 13 and 52. The German version of the PAM-13 (PAM-13-G) is validated and demonstrates good psychometric properties, including good internal consistency (Cronbach's α = 0.84). In this study, raw scores were converted into the standardized 0-100 patient activation score using a min-max transformation, with higher scores indicating greater patient activation and thus a better outcome.
Results for this outcome have not been posted.
The WSAS is a 5-item self-report scale to measure social functioning in regard to physical, mental and social health as well as age group referenced competence for performance. The PROM has good psychometric properties with good criterion validity, good sensitivity and strong internal consistency (α = 0.89). Individual items address work, home management, social leisure, private leisure and relationships. Each item is rated on a 9-point Likert scale from 0 = "not at all impaired" to 8 = "very severely impaired". The total score ranges from 0 to 40. Higher total scores indicate greater functional impairment and thus a worse outcome, whereas lower scores indicate less disability and a better outcome.
Results for this outcome have not been posted.
Costs caused due to BPD will be assessed with a self-compiled instrument assessing inpatient and outpatient treatment, support from friends, family and professional services, contacts with members of the judicial authorities and public security, medication, sick leave, and physician/therapist visits during work time. Higher values indicate greater resource utilization and higher costs and thus a worse economic outcome, whereas lower values indicate lower resource use and a better economic outcome.
Results for this outcome have not been posted.
This self-administered patient questionnaire is used as a screening tool and severity measure for generalized anxiety disorder (GAD). Studies report good reliability, as well as criterion, construct, factorial, and procedural validity. The GAD-7 is scored on a Likert scale ranging from 0 = "not at all" via 1 = "several days" and 2 = "more than half the days" to 3 = "nearly every day", yielding a sum score ranging from 0-21. Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively. Higher total scores indicate greater anxiety symptom severity and thus a worse outcome, whereas lower scores indicate fewer anxiety symptoms and a better outcome.
Results for this outcome have not been posted.
The PHQ-9 is the 9-item depression module from the full PHQ with comparable sensitivity and specificity, and includes the 9 criteria upon which the diagnosis of DSM-IV depressive disorders is based. Rating is done on a 4-point Likert scale ranging 0 = "not at all" to 3 = "nearly every day". As a severity measure, scores range from 0 to 27 and represent: mild (0-4), moderate (5-9), moderately severe (10-14), and severe depression (≥15). According to several studies, the German version can be considered reliable regarding psychometric standards. Higher total scores indicate greater depressive symptom severity and thus a worse outcome, whereas lower scores indicate fewer depressive symptoms and a better outcome.
Results for this outcome have not been posted.
The BSL-23 is a 23-item PROM with good psychometric properties that was validated and tested for reliability in a representative German sample (test-retest reliability r = .82, p \< 0.0001; α = 0.94-0.97; high correlation of total score with general psychological burden and depression) to assess the typical symptomatology and severity of BPD. It refers to the last week and has a range from 0 = "not at all" to 4 = "very strong". Its single factor structure was optimized to reflect levels and changes in severity of BPD-symptomatology based on a mean score. Higher mean scores indicate greater symptom severity and thus a worse outcome, whereas lower scores indicate fewer BPD-related symptoms and a better outcome.
Results for this outcome have not been posted.
Collected over 3 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Alivis + Treatment as Usual (TAU) | 0/97 (0%) | 0/97 (0%) | 0/97 (0%) |
| Treatment as Usual (TAU) | 0/96 (0%) | 0/96 (0%) | 0/96 (0%) |
Subset used for interim futility analysis. N is lower than total enrollment due to data cut-off.
| Age, Continuous(Years) | Alivis + Treatment as Usual (TAU) | Treatment as Usual (TAU) | Total |
|---|---|---|---|
| Mean | 30.70 ± 8.37 | 31.77 ± 8.34 | 31.23 ± 8.35 |
| Sex: Female, Male(Participants) | Alivis + Treatment as Usual (TAU) | Treatment as Usual (TAU) | Total |
|---|---|---|---|
| Female | 89 | 90 | 179 |
| Male | 8 | 6 | 14 |
| Race/Ethnicity, Customized(Participants) | Alivis + Treatment as Usual (TAU) | Treatment as Usual (TAU) | Total |
|---|---|---|---|
| White | 94 | 89 | 183 |
| Other | 3 | 7 | 10 |
| BSL-23(Score) | Alivis + Treatment as Usual (TAU) | Treatment as Usual (TAU) | Total |
|---|---|---|---|
| Mean | 2.32 ± 0.66 | 2.45 ± 0.61 | 2.38 ± 0.64 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: No
This study is terminated, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Borderline Personality Disorder→
Gaia AG